1. Women or men aged between 18 and 64, 2. Presence of COVID-19 pneumonia (Chest X-ray or CTPA evidence, as assessed by the treating physician), 3. Patient is admitted to hospital due to COVID-19 pneumonia, 4. Laboratory-confirmed SARS-CoV-2 infection (e.g., by PCR, antigen), 5. The patient's ability to cooperate and express his/her consent with the study participation, 6. Women of childbearing potential must have a negative pregnancy test (urine or serum) at screening and must agree to use highly effective contraceptive method from the day of enrollment in the study until 7 days (5 half-lives of bazedoxifene) after the last administered dose of IMP. As highly effective contraceptive method is considered: a. implantable intrauterine device (excluding hormone release system) b. bilateral tubal occlusion in females c. vasectomized male/partner d. sexual abstinence 7. Non-fertile man or fertile man who agree with sexual abstinence or using condom from the day of enrollment in the study until 7 days (5 half-lives of bazedoxifene) after the last administered dose of IMP, 8. Signed Informed Consent Form for participation in the study.

1. Women or men aged between 18 and 64, 2. Presence of COVID-19 pneumonia (Chest X-ray or CTPA evidence, as assessed by the treating physician), 3. Patient is admitted to hospital due to COVID-19 pneumonia, 4. Laboratory-confirmed SARS-CoV-2 infection (e.g., by PCR, antigen), 5. The patient's ability to cooperate and express his/her consent with the study participation, 6. Women of childbearing potential must have a negative pregnancy test (urine or serum) at screening and must agree to use highly effective contraceptive method from the day of enrollment in the study until 7 days (5 half-lives of bazedoxifene) after the last administered dose of IMP. As highly effective contraceptive method is considered: a. implantable intrauterine device (excluding hormone release system) b. bilateral tubal occlusion in females c. vasectomized male/partner d. sexual abstinence 7. Non-fertile man or fertile man who agree with sexual abstinence or using condom from the day of enrollment in the study until 7 days (5 half-lives of bazedoxifene) after the last administered dose of IMP, 8. Signed Informed Consent Form for participation in the study.